News Releases

Date	Title and Summary	View
Feb 05, 2021	Johnson & Johnson to Participate in the Cowen 41st Annual Health Care Virtual Conference
Feb 04, 2021	Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Feb 03, 2021	Johnson & Johnson to Participate in the Raymond James 42nd Annual Institutional Investors Conference
Feb 02, 2021	JOHNSON & JOHNSON VISION RECEIVES FDA APPROVAL FOR NEXT GENERATION MONOFOCAL INTRAOCULAR LENS - TECNIS EYHANCE™ AND TECNIS EYHANCE™ TORIC II IOLS - FOR THE TREATMENT OF CATARACT PATIENTS
Feb 02, 2021	Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
Feb 01, 2021	Janssen Announces CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
Jan 29, 2021	Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination 85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28 Protection
Jan 27, 2021	Johnson & Johnson to Participate in the Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
Jan 26, 2021	Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year Results - 2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of 7.1%* and adjusted operational growth of 7.3%* - 2020 Full-Year Sales of $82.6 Billion reflecting growth of 0.6%, operational growth of 1.2%* and adjusted operational growth of 1.5%* - 2020 Fourth-Quarter
Jan 21, 2021	Auris Health Announces Publication of Results from BENEFIT Study of MONARCH® Platform in CHEST